Stock MYO MYOMO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Myomo, Inc.

Equities

MYO

US62857J2015

Market Closed - Nyse
Other stock markets
 21:00:00 15/05/2024 BST 		5-day change 1st Jan Change
3.78 USD +5.59% Intraday chart for Myomo, Inc. -3.82% -24.55%
05-08 Transcript : Myomo, Inc., Q1 2024 Earnings Call, May 08, 2024
05-08 Myomo, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
MYOMO, INC. Stock Myomo, Inc.
-24.55% 103M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-4.98% 181B
C+
MEDTRONIC PLC Stock Medtronic plc
+2.84% 112B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-2.68% 67.92B
A
DEXCOM, INC. Stock DexCom, Inc.
+4.53% 50.1B
B-
CENCORA, INC. Stock Cencora, Inc.
+8.00% 44.27B
B-
HOYA CORPORATION Stock Hoya Corporation
+9.39% 40.41B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+25.30% 31.95B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-0.17% 25.82B
A-
TERUMO CORPORATION Stock Terumo Corporation
+17.27% 25.29B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MYO Stock
  4. Ratings Myomo, Inc.